Dyadic International, Inc.

188 articles with Dyadic International, Inc.

• Dyadic to Report Second Quarter 2021 Financial Results

  7/29/2021

  Dyadic International, Inc. announced that it will report its financial results for quarter ended June 30, 2021 and host a corporate update conference call on Thursday, August 12, 2021.

• Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

  7/27/2021

  Dyadic International, Inc., announced it signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium, a South African-based company whose mission is to develop a South African-based solution for the discovery, development, evaluation and manufacture of high-quality, cost-effective vaccines for distribution primarily to the African markets.

• Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal

  6/28/2021

  Dyadic announced today findings from the Zoonotic Anticipation and Preparedness Initiative (ZAPI) project which has been published in VACCINES, a leading peer-reviewed scientific journal. 

• 

  Dyadic announces development of COVID-19 Vaccine in IndiaIn collaboration with Syngene Internatio...

  5/26/2021

  Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic ...

• Dyadic to Present at Upcoming Events - May 24, 2021

  5/24/2021

  Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced that the Company will participate in the following upcoming events

• Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

  5/13/2021

  Dyadic International, Inc., a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics announced its financial results for the first quarter of 2021 and highlighted recent Company progress.

• Dyadic to Present at Upcoming Events - May 03, 2021

  5/3/2021

  Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced that the Company will participate in the following upcoming events

• Dyadic to Report First Quarter 2021 Financial Results

  4/29/2021

  Dyadic International, Inc. announced that it will report its financial results for quarter ended March 31, 2021 and host a corporate update conference call on Thursday, May 13, 2021.

• Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time

  4/22/2021

  Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of vaccines, therapeutics and other protein based products today announced that it will host a fireside chat on Tuesday, May 4, 2021 at 10:00am Eastern Time

• Dyadic Reports 2020 Year End Results and Recent Company Progress

  3/30/2021

  Advancing Dyadics proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercialization

• Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

  3/22/2021

  Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines) Exclusive license for Republic of Korea and multiple Southeast Asian countries

• Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100

  3/18/2021

  Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice vaccinated with SARS-CoV-2-S-RBD vaccine candidate manufactured from C1-cells

• Dyadic to Report Fourth Quarter and Full Year 2020 Financial Results

  3/16/2021

  Dyadic International, Inc. (NASDAQ:DYAI),today announced that it will report its financial results for full year ended December 31, 2020 and host a corporate update conference call on Tuesday, March 30, 2021.

• Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting

  3/9/2021

  Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today is updating the market on the Company’s key scientific achievements reported in Zoonotic Anticipation

• Dyadic to Present at Upcoming Events

  2/15/2021

  Dyadic International, Inc. (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Companys management will be attending and presenting at the following upcoming events

• Dyadic to Present at ZAPI Stakeholders Virtual Meeting

  2/3/2021

  Dyadic International, Inc. today announced that Ronen Tchelet, PhD, Dyadic's Chief Scientific Officer, will make a presentation during the European Union Innovative Medicines Initiative (IMI) Zoonotic Anticipation Preparedness Initiative - ZAPI Stakeholders Virtual Web Meeting to be held on February 4th and 5th, 2020.

• Dyadic Enters Collaboration with TurtleTree Scientific to Develop Recombinant Protein Growth Factors

  2/2/2021

  Dyadic International, Inc. a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of vaccines, drugs and other biological products at flexible commercial scales, today announced a fully funded collaboration with TurtleTree Scientific to develop a number of recombinant protein growth factors

• Dyadic International Appoints New Board Member

  1/11/2021

  Dyadic International, Inc. , today announced the appointment of Patrick Lucy, to its Board of Directors, effective January 8, 2021.

• Dyadic to Interview with FOX Business Network on Wednesday December 9, 2020

  12/9/2020

  Dyadic International, Inc. , a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb, has confirmed an interview with FOX Business Network for the following program today:

• Dyadic Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress

  11/12/2020

  Dyadic International, Inc., a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced its financial results for the quarter ended September 30, 2020, and recent developments.